Tetraphase pharmaceuticals inc (TTPH)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenues:
Total revenue

7,376

18,904

9,666

-

-

-

-

-

-

Expenses:
Total revenues

-

-

-

5,145

11,686

9,098

10,486

7,600

185

Research and development

22,785

54,879

101,706

63,764

73,768

61,932

31,508

17,294

17,737

Selling, general and administrative

49,043

37,078

23,675

-

-

-

-

-

-

Total expenses

74,908

92,185

125,381

-

-

-

-

-

-

General and administrative

-

-

-

19,211

20,916

12,932

7,168

4,309

3,874

Total operating expenses

-

-

-

82,975

94,684

74,864

38,676

21,603

21,611

Loss from operations

-67,532

-73,281

-115,715

-77,830

-82,998

-65,766

-28,190

-14,003

-21,426

Other income and expenses
Loss on extinguishment of debt

-1,568

-

-

-

-

-

-

-

-

Other income

333

-

-

-

-

-

-

-

-

Interest income

1,262

1,747

963

-

-

17

10

-

1

Interest expense

2,580

624

-

-

-

1,017

1,719

1,021

161

Other income (expense)

-

-

-

350

-191

24

263

-63

22

Other income (expense), net

-

-

-

350

-191

-976

-1,446

-1,084

-138

Net loss

-70,085

-72,158

-114,752

-77,480

-83,189

-66,742

-29,636

-15,087

-21,564

Net loss per share-basic and diluted

-22.85

-27.48

-2.63

-2.11

-2.36

-2.49

-1.78

-47.54

-73.34

Weighted-average number of common shares used in net loss per share-basic and diluted

3,067

2,626

43,582

36,704

35,261

26,807

16,665

317

294

Comprehensive loss

-70,085

-72,158

-114,752

-77,480

-83,189

-66,742

-29,636

-15,087

-21,564

Product Revenue, net [Member]
Total revenue

3,575

178

-

-

-

-

-

-

-

Cost of revenue

2,687

130

-

-

-

-

-

-

-

License and Collaboration Revenue [Member]
Total revenue

2,000

12,677

-

-

-

-

-

-

-

Government Revenue [Member]
Total revenue

1,801

6,049

9,666

-

-

-

-

-

-

Intangible asset amortization [Member]
Cost of revenue

393

98

-

-

-

-

-

-

-